Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Kymera Therapeutics Showcased New Clinical Findings From The Ongoing Phase 1 Study Of Its MDM2 Degrader, KT-253, At The ASCO 2024

Author: Benzinga Newsdesk | June 03, 2024 04:40am

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients
KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors
KT-253 Phase 1 study ongoing with additional data expected in the second half of 2024

Posted In: KYMR